Thus, through its integral role in hepatic lipid metabolism, inflammatory signaling, and the regulation of ER stress and cell death pathways, FoxO1 and its associated regulatory network emerge as a compelling therapeutic target for NAFLD. Here, FOXO1 is linked to metabolic dysfunction-associated steatotic liver disease.